Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.
creatinine
cystatin C
hepatocellular carcinoma
liver disease
muscle atrophy
overestimation of renal function
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
28
02
2022
received:
07
12
2021
accepted:
12
03
2022
pubmed:
31
3
2022
medline:
31
3
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
A high prevalence of overestimated renal function in patients with liver cirrhosis (LC) has been reported; nonetheless, its impact on prognosis remains unclear. We aimed to evaluate the impact of overestimated renal function on prognosis in patients with LC. An overestimated renal function was defined as a >20% increase in the creatinine-based estimated glomerular filtration rate (eGFR), compared with cystatin C-based eGFR. LC patients with conserved serum, who were evaluated for muscle atrophy and had proper clinical information were included, and their prognostic factors were analyzed. A total of 215 consecutive patients with LC were included. The prevalence of overestimated renal function was 29.8% (64/215). Kaplan-Meier survival analysis revealed that patients with overestimated renal function had a poorer prognosis than those without overestimated renal function (hazard ratio [HR]: 2.217 95% confidence interval [CI]: 1.290-3.810; p = 0.001). Subgroup analysis showed that overestimated renal function was a significant prognostic factor, irrespective of sex and the presence of hepatocellular carcinoma (HCC). Multivariate Cox regression analyses revealed that overestimated renal function was a significant and independent factor predictive of poor prognosis in the entire cohort (HR: 2.050; 95% CI: 1.041-4.037; p = 0.038) and in subgroups classified by Child-Pugh class A (HR: 2.131; 95% CI: 1.019-4.458; p = 0.044), Model for End-Stage Liver Disease score ≤9 (HR: 2.303; 95% CI: 1.038-5.109; p = 0.04), and presence of HCC (HR: 2.290; 95% CI: 1.128-4.651; p = 0.022). Overestimated renal function is a significant and independent prognostic factor in patients with LC.
Types de publication
Journal Article
Langues
eng
Pagination
603-613Subventions
Organisme : Kakenchi
ID : 19K08458
Organisme : Japan Agency for Medical Research and Development
ID : JP21fk0210058, JP21fk0210066, JP21fk0210067
Organisme : Japan Agency for Medical Research and Development
ID : JP21fk0210064, JP21fk0210056, JP21fk0210048
Organisme : Japan Agency for Medical Research and Development
ID : JP21fk0210072, JP21fk0310101, JP21fk0210047
Informations de copyright
© 2022 Japan Society of Hepatology.
Références
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725-49.
Nakai M, Suda G, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, et al. Durable response without recurrence to Tolvaptan improves long-term survival. J Gastroenterol. 2020;55:1150-61.
Hidaka H, Nakazawa T, Kutsukake S, Yamazaki Y, Aoki I, Nakano S, et al. The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. J Gastroenterol. 2013;48:269-76.
Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792-801.
Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56:810-18.
Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246-56. 56 e1-5.
Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008;48:1002-10.
Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition)Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46:951-63.
Yoo JJ, Kim SG, Kim YS, Lee B, Lee MH, Jeong SW, et al. Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex. J Hepatol. 2019;70:847-54.
Francoz C, Sola E. Assessment of renal function in cirrhosis: sarcopenia, gender and ethnicity matter. J Hepatol. 2019;70:828-30.
Yoshida S, Suda G, Ohara M, Fu Q, Yang Z, Hosoda S, et al. Frequency and characteristics of overestimated renal function in Japanese patients with chronic liver disease and its relation to sarcopenia. Nutrients. 2021;13.
Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017;37(Suppl 1):116-22.
Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193-9.
Iritani S, Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015;50:323-32.
Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63:131-40.
Sola E, Gines P. Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. Liver Int. 2015;35:2079-81.
Tokuchi Y, Suda G, Kimura M, Maehare O, Kitagataya T, Ohara M, et al. Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: impact of changes in skeletal muscle mass. J Viral Hepat. 2021;28(5):755-63.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-92.
Japan Nephrology Society. [Special issue: clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012]. Nihon Jinzo Gakkai Shi. 2012;54:1034-191.
Ohara M, Suda G, Kimura M, Maehara O, Shimazaki T, Shigesawa T, et al. Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. JCSM Rapid Comm. 2020;3:103-14.
Ohara M, Suda G, Kimura M, Maehara O, Shimazaki T, Shigesawa T, et al. Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol Res. 2020;50:715-25.
Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, et al. L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun. 2018;2:906-18.
Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Kubo A, et al. Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. Sci Rep. 2021;11:16616.
Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, et al. High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res. 2020;50:671-81.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56:593-619.
Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and frailty in liver cirrhosis. Life. 2021;11:399.
Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2021;36:1812-19.
Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25:550-7.
Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017;66:1232-41.